{"id":"W4206960604","doi":"","title":"KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.","year":2022,"lang":"en","type":"article","venue":"Bern Open Repository and Information System (University of Bern)","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Aflibercept; Medicine; Dosing; Clinical endpoint; Diabetic retinopathy; Adverse effect; Visual acuity; Macular edema; Randomized controlled trial; Ophthalmology; Surgery; Internal medicine; Diabetes mellitus; Chemotherapy; Bevacizumab; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004363231,0.001426259,0.002002537,0.0004520297,0.0004121153,0.001318588,0.001056986,0.002282943,0.005441752],"category_scores_gemma":[0.00390823,0.0006111303,0.00206785,0.0003926512,0.0007002588,0.001162788,0.0004784149,0.003870236,0.001250083],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007383385,"about_ca_system_score_gemma":0.0009606832,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001558078,"about_ca_topic_score_gemma":0.003867205,"domain_scores_codex":[0.9988378,0.0006234296,0.00006214979,0.0001055623,0.0001298017,0.0002413185],"domain_scores_gemma":[0.9970859,0.0009470999,0.0005865795,0.0002433781,0.0001918452,0.0009452641],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8376727,0.01322564,0.003123539,0.001293263,0.002987414,0.000244806,0.0002173818,0.001835719,0.01398397,0.0002996018,0.01509861,0.1100174],"study_design_scores_gemma":[0.8402153,0.1193378,0.02626823,0.0002030396,0.002024439,0.0003951551,0.0001349528,0.0009450356,0.002309686,0.0003563955,0.007717218,0.00009265012],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9334732,0.04228815,0.001279877,0.004506417,0.0007491987,0.002203939,0.008098479,0.0002597468,0.007140983],"genre_scores_gemma":[0.9680399,0.01023082,0.002247212,0.00348889,0.0003965977,0.001543561,0.007700521,0.00009243338,0.006259995],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005441752,"threshold_uncertainty_score":0.02307522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02779509310067557,"score_gpt":0.2721787307493523,"score_spread":0.2443836376486767,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}